Tocilizumab in Active Moderate-severe Graves' Orbitopathy

NCT04876534 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Graves Ophthalmopathy

Interventions

DRUG: Tocilizumab 20 Mg/mL Intravenous Solution
DRUG: MethylPREDNISolone Injectable Solution

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]